Modeling undetected poliovirus circulation following the 2022 outbreak in the United States
Kalkowsa DA, Badizadegan K, Routh JA, Burns CC, Rosenberg ES, Brenner IR, Zucker JR, Langdon-Embry M, Thompson KM
Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization
Thompson KM, Kalkowsa DA, Kidd SE, Burns CC, Badizadegan K
Oral polio vaccine stockpile modeling: insights from recent experience
Thompson KM, Kalkowska DA, Badizadegan K
Expert Rev Vaccines, 2023; 22(1):813-825. doi:10.1080/14760584.2023.2263096.
Health economic analysis of antiviral drugs in the global polio eradication endgame
Badizadegan K, Kalkowska DA, Thompson KM
Med Decis Making, 2023:272989x231191127. doi:10.1177/0272989x231191127.
Modeling poliovirus transmission and responses in New York State
Thompson KM, Kalkowska DA, Routh JA, Brenner IR, Rosenberg ES, Zucker JR, Langdon-Embry M, Sugerman DE, Burns CC, Badizadegan K
J Infec Dis 2023 Aug 19;jiad355. doi:10.1093/infdis/jiad355. Online ahead of print.
Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences
Kalkowska DA, Wassilak SGF, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, Thompson KM
Risk Anal, 2023, online ahead of print. doi:10.1111/risa.14158.
Worst-case scenarios: Modeling uncontrolled type 2 polio transmission
Kalkowska DA, Wiesen E, Wassalik SGF, Burns CC, Pallansch MA, Badizadegan K, Thompson KM
Risk Anal, 2023, online ahead of print. doi:10.1111/risa.14159.
Pinned Video: The U.S. Centers for Disease Control & Prevention (CDC) and Kid Risk, Inc.: Polio eradicators use integrated analytical models to make better decisions
Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL
2014 Edelman Award lecture & presentation slides
Polio endgame complexity: updating expectations for nOPV2
Thompson KM
Lancet Infect Dis, 2023; S1473-3099(23)00133-0. doi:10.1016/S1473-3099(23)00133-0.
Outbreak management strategies for cocirculation of multiple poliovirus types
Kalkowska DA, Badizadegan K, Thompson KM
Vaccine, 2023; doi:10.1016/j.vaccine.2023.04.037.
Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation
Kalkowsa DA, Wassilak SGF, Wiesen E, Estivariz CF, Burns CC, Badizadegan K, Thompson KM
Gates Open Res, 2023; 7:55. doi: 10.12688/gatesopenres.14511.1. eCollection 2023..
Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation
Thompson KM, Kalkowska DA, Badizadegan K
Front Public Health, 2023; 11. doi:10.3389/fpubh.2023.1098419.
Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame
Thompson KM
Lancet Glob Health, 2022; 10(12):e1697-e1698. doi:10.1016/S2214-109X(22)00452-1.
Polio eradication: Addressing the hurdles on the last mile
Thompson KM, Lauring AS, Pollard AJ, Andino R, Bandyopadhyay AS, Berkley S, Bhutta ZA, Routh J, Benn CS
Cell, 2023; 186(1):1-4. doi:10.1016/j.cell.2022.12.021.
Outbreak response strategies with type 2-containing oral poliovirus vaccines
Kalkowsa DA, Wassilak SGF, Pallansch MA, Burns CC, Wiessen ED, Badizadegan K, Thompson KM
Vaccine, 2023; 41 Suppl 1:A142-A152. (Epub date 20221117) doi:10.1016/j.vaccine.2022.10.060.
Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036
Thompson KM, Kalkowska DA, Badizadegan K
Expert Rev Vaccines, 2022. 21(11):1667-1674. doi:10.1080/14760584.2022.2128108.
Polio by the Numbers – A Global Perspective
Badizadegan K, Kalkowska DA, Thompson KM
J Infect Dis, 2022. 226(8):1309–1318. doi:10.1093/infdis/jiac130.
Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan
Kalkowsa DA, Badizadegan K, Thompson KM
Risk Anal, 2023. 43(4):677-685. doi: 10.1111/risa.13982. Epub 2022 Jun 23.
Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan
Kalkowsa DA, Badizadegan K, Thompson KM
Risk Anal, 2023. 43(4):660-676. doi: 10.1111/risa.13983. Epub 2022 Jun 23.
Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative
Thompson K, Kalkowska D, Badizadegan K
Gates Open Research, 2022; 6(5). doi:10.12688/gatesopenres.13524.1.
Health economic analyses of secondary vaccine effects: a systematic review and policy insights
Thompson KM, Badizadegan K
Expert Rev Vaccines, 2022:1-16. doi:10.1080/14760584.2022.2017287.
Polio eradication: what kind of world do we want?
Thompson KM
Lancel Infect Dis, 2022; 22(2):161-163. doi:10.1016/S1473-3099(21)00458-8.
Modeling poliovirus surveillance and immunization campaign quality monitoring costs for Pakistan and Afghanistan for 2019-2023
Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM
Open Forum Infect Dis, 2021. doi:10.1093/ofid/ofab264.
Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response
Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM
Vaccine, 2023; 41 Suppl 1:A136-A141. (Epub date 20210514) doi:10.1016/j.vaccine.2021.04.061.
The impact of disruptions caused by the COVID-19 pandemic on global polio eradication
Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, Thompson KM
Vaccine, 2023; 41 Suppl 1:A12-A18. (Epub date 20210427) doi:10.1016/j.vaccine.2021.04.026.
Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options
Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM
J Infect Dis, 2021. doi:10.1093/infdis/jiab160.
Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions
Thompson KM, Kalkowska DA, Badizadegan K
Expert Rev Vaccines, 2021. doi:10.1080/14760584.2021.1891888.
Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication
Thompson KM, Kalkowska DA, Badizadegan K
Expert Rev Vaccines, 2021. doi:10.1080/14760584.2021.1891889.
Health and economic outcomes associated with polio vaccine policy options: 2019–2029
Kalkowska DA, Thompson KM
Risk Anal, 2021; 41(2):364-375. doi:10.1111/risa.13664.
Modeling and managing poliovirus risks: We are where we are…
Thompson KM
Risk Anal, 2021; 41(2):223-228. doi:10.1111/risa.13668.
An updated economic analysis of the global polio eradication initiative
Thompson KM, Kalkowska DA
Risk Anal, 2021; 41(2):393-406. doi:10.1111/risa.13665.
Poliovirus vaccine options: another step forward
Thompson KM
The Lancet, 2021. doi:10.1016/S0140-6736(20)32629-5.
Updated characterization of outbreak response strategies for 2019-2029: Impacts of using a novel type 2 oral poliovirus vaccine strain
Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM
Risk Anal, 2021. doi:10.1111/risa.13622.
No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]
Thompson KM, Kalkowska DA, Badizadegan K
Risk Anal, 2021; 41(2):389-392. doi:10.1111/risa.13671.
A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States
Thompson KM, Kalkowska DA, Badizadegan K
Risk Anal, 2021; 41(2):376-386. doi:10.1111/risa.13614.
Expected implications of globally coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV
Kalkowska DA, Thompson KM
Risk Anal, 2021; 41(2):312-319. doi:10.1111/risa.13590.
Potential future use, costs, and value of poliovirus vaccines
Thompson KM, Kalkowska DA
Risk Anal, 2021; 41(2):349-363. doi:10.1111/risa.13557.
Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart
Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM
Risk Anal, 2021; 41(2):320-328. doi:10.1111/risa.13555.
Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
Thompson KM, Kalkowska DA
Expert Rev Vaccines, 2020:1-25. doi:10.1080/14760584.2020.1791093.
Reflections on modeling poliovirus transmission and the polio eradication endgame
Thompson KM, Kalkowska DA
Risk Anal, 2021; 41(2):229-247. doi:10.1111/risa.13484.
Modeling undetected live poliovirus circulation after apparent interruption of transmission: Borno and Yobe in northeast Nigeria
Kalkowska DA, Thompson KM
Risk Anal, 2021; 41(2):303-311. doi:10.1111/risa.13486.
Modeling poliovirus transmission in Borno and Yobe, northeast Nigeria
Kalkowska DA, Franka R, Higgins J, Kovacs SD, Forbi JC, Wassilak SGF, Pallansch MA, Thompson KM
Risk Anal, 2021; 41(2):289-302. doi:10.1111/risa.13485.
Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan
Kalkowska DA, Thompson KM
Risk Anal, 2020. doi:10.1111/risa.13471.
The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization
Badizadegan K, Goodson JL, Rota PA, Thompson KM
Expert Rev Vaccines, 2020; 19(2):175-194. doi:10.1080/14760584.2020.1732215.
Global transmission of live polioviruses: Updated dynamic modeling of the polio endgame
Kalkowska DA, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM
Risk Anal, 2020. doi: 10.1111/risa.13447. Epub 2020 Jan 20.
Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters
Kalkowska DA, Pallansch MA, Thompson KM
Epidemiol Infect, 2019; published online 24 October 2019, e295.
Logistical challenges and assumptions for modeling the failure of global cessation of oral Poliovirus vaccine (OPV)
Thompson KM, Kalkowska DA
Expert Rev Vaccines, 2019 Jul;18(7):725-736. doi: 10.1080/14760584.2019.1635463. Epub 2019 Jul 2.
Polio endgame options: Will we have the vaccines needed?
Thompson KM
Lancet, 2019 Jul 13;394(10193):99-100. doi: 10.1016/S0140-6736(19)31294-2. Epub 2019 Jun 4.
Characterizing the costs of the global polio laboratory network: A survey-based analysis
Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM
BMJ Open, 2019 Jan 21;9(1):e023290. doi: 10.1136/bmjopen-2018-023290.
Global certification of wild poliovirus eradication: Insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission
Duintjer Tebbens RJ, Kalkowska DA, Thompson KM
BMJ Open, 2019 Jan 15;9(1):e023938. doi: 10.1136/bmjopen-2018-023938.
Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan
Duintjer Tebbens RJ, Thompson KM
Risk Anal, 2019 Feb;39(2):389-401. doi: 10.1111/risa.13194. Epub 2018 Sep 21.
Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan
Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM
Risk Anal, 2019 Feb;39(2):402-413. doi: 10.1111/risa.13214. Epub 2018 Oct 8.
Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation
Kalkowska DA, Duintjer Tebbens RJ, Thompson KM
Risk Anal, 2019 Feb;39(2):414-425. doi: 10.1111/risa.13193. Epub 2018 Sep 21.
Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
Duintjer Tebbens RJ, Thompson KM
Expert Rev Vaccines, 2018 Aug;17(8):739-751. doi: 10.1080/14760584.2018.1506333. Epub 2018 Aug 9.
Another look at silent circulation of poliovirus in small populations
Kalkowska DA, Duintjer Tebbens RJ, Thompson KM
Infectious Disease Modeling, 2018; 3:107-117. doi:10.1016/j.idm.2018.06.001.
Poliovirus containment risks and their management
Duintjer Tebbens RJ, Kalkowska DA, Thompson KM
Future Virology, 2018; 13(9):617-628, doi: 10.2217/fvl-2018-0079.
Using integrated modeling to support the global eradication of vaccine-preventable diseases
Thompson KM, Duintjer Tebbens RJ
System Dynamics Review, 2018;34(1-2):78-120. doi:10.1002/sdr.1589.
Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
Duintjer Tebbens RJ, Hampton LM, Thompson KM
BMC Infect Dis, 2018; 18:165. doi:10.1186/s12879-018-3074-0.
Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations
Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM
Risk Anal, 2018 Aug;38(8):1701-1717. doi: 10.1111/risa.12962. Epub 2018 Jan 3.
Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission
Thompson KM, Duintjer Tebbens RJ
J Infect Dis, 2017 Jul 1;216(suppl_1):S176-S182. doi: 10.1093/infdis/jix108.
Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes
Thompson KM, Duintjer Tebbens RJ
J Infect Dis, 2017 Jul 1;216(suppl_1):S168-S175. doi: 10.1093/infdis/jix128.
Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems
Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM
Food Environ Virol, 2017 Dec;9(4):361-382. doi: 10.1007/s12560-017-9314-4. Epub 2017 Jul 7.
Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
Duintjer Tebbens RJ, Thompson KM
Vaccine, 2017 Jul 5;35(31):3823-3833. doi: 10.1016/j.vaccine.2017.05.090. Epub 2017 Jun 9.
Poliovirus vaccination during the endgame: insights from integrated modeling
Duintjer Tebbens RJ, Thompson KM
Expert Rev Vaccines, 2017 Jun;16(6):577-586. doi:10.1080/14760584.2017.1322514. Epub 2017 May 9.
Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use
Duintjer Tebbens RJ, Thompson KM
Medical Decision Making Policy & Practice, 2017; 2(1):1-13, doi:10.1177/2381468317697002.
How should we prepare for an outbreak of reintroduced live polioviruses?
Thompson KM, Duintjer Tebbens RJ
Future Virology, 2017; 12(2):41-44, doi:10.2217/fvl-2016-0131.
The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management
Duintjer Tebbens RJ, Thompson KM
Future Microbiology, 2016; 11(12):1549-1561, doi:10.2217/fmb-2016-0126
Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
Duintjer Tebbens RJ, Thompson KM
Epidemiology and Infection, 2017; 145(2):217-226, doi: 10.1017/S0950268816002302.
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
Duintjer Tebbens RJ, Hampton LM, Thompson KM
BMC Infect Dis, 2016; 16:237. doi:10.1186/s12879-016-1537-8.
Uncertainty and Sensitivity Analysis of Cost Assumptions for Global Long-term Poliovirus Risk Management
Duintjer Tebbens RJ, Thompson KM
J Vaccines Vaccin, 2016; 7(5):1000339. doi:10.4172/2157-7560.1000339.
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
Duintjer Tebbens RJ, Hampton LM, Thompson KM
BMC Infect Dis, 2016; 16:231. doi:10.1186/s12879-016-1536-9.
Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation
Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM
J Vaccines Vaccin, 2016; 7(5). doi:10.4172/2157-7560.1000340.
Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame
Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM
BMC Infect Dis, 2016; 16:137. doi:10.1186/s12879-016-1465-7.
Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
Duintjer Tebbens RJ, Thompson KM
BMC Infect Dis, 2015; 15:390. doi:10.1186/s12879-015-1114-6.
Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
Duintjer Tebbens RJ, Pallansch MA, Thompson KM
BMC Infect Dis, 2015; 15:379. doi:10.1186/s12879-015-1115-5.
An economic analysis of poliovirus risk management policy options for 2013-2052
Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM.
BMC Infect Dis, 2015; 15:389. doi:10.1186/s12879-015-1112-8.
Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
Thompson KM, Duintjer Tebbens RJ
BMC Infect Dis, 2015; 15:374. doi:10.1186/s12879-015-1113-7.
The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
Thompson KM, Duintjer Tebbens RJ
BMC Infect Dis, 2015; 15:376. doi:10.1186/s12879-015-1116-4.
Good news for billions of children who will receive IPV
Thompson KM
Lancet Infect Dis, 2015; 15(10):1120-1122. doi:10.1016/S1473-3099(15)00099-7.
Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria
Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM
PLoS One, 2015; 10(6):e0130123. doi:10.1371/journal.pone.0130123.
Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data
Thompson KM, Logan GE; Florida SHOTS™ Research Team
Risk Anal, 2016;36(7):1418-26. doi: 10.1111/risa.12424. Epub 2015 May 29.
Polio eradicators use integrated analytical models to make better decisions
Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL
Interfaces, 2015; 45(1):5-25.
Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses
Thompson KM, Kalkowska DA, Duintjer Tebbens RJ
Vaccine, 2015; 33(13):1568-77. doi:10.1016/j.vaccine.2015.02.013.
Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination
Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM
BMC Infect Dis, 2015; 15:66. doi:10.1186/s12879-015-0791-5.
Modeling options to manage population immunity and the impact of asymptomatic wild poliovirus transmission in Israel
Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM
J Infect Dis, 2015; 211(11):1800-12. doi:10.1093/infdis/jiu674.
Modeling the dynamics of oral poliovirus vaccine cessation
Thompson KM, Duintjer Tebbens RJ
J Infect Dis, 2014; 210 Suppl 1:S475-84. doi:10.1093/infdis/jit845.
Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination
Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM
J Infect Dis, 2014; 210 Suppl 1:S424-33. doi:10.1093/infdis/jit843.
Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation
Duintjer Tebbens RJ, Thompson KM
J Infect Dis, 2014; 210 Suppl 1:S485-97. doi:10.1093/infdis/jit838.
Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India
Kalkowska DA, Duintjer Tebbens RJ, Thompson KM
J Infect Dis, 2014; 210 Suppl 1:S398-411. doi:10.1093/infdis/jit844.
Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria
Kalkowska DA, Duintjer Tebbens RJ, Thompson KM
J Infect Dis, 2014; 210 Suppl 1:S412-23. doi:10.1093/infdis/jit834.
Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine
Thompson KM
Lancet, 2014; 384(9953):1480-2. doi:10.1016/S0140-6736(14)60983-1.
The potential impact of expanding target age groups for polio immunization campaigns
Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM
BMC Infect Dis, 2014; 14:45. doi:10.1186/1471-2334-14-45.
National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication
Thompson KM, Duintjer Tebbens RJ
Expert Rev Vaccines, 2014; 13(2):221-34. doi:10.1586/14760584.2014.864563.
Preeradication vaccine policy options for poliovirus infection and disease control
Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL
Risk Anal, 2013; 33(4):516-43. doi:10.1111/risa.12019.
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)
Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM
Risk Anal, 2013; 33(4):680-702. doi:10.1111/risa.12022.
Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses
Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM
Risk Anal, 2013; 33(4):703-49. doi:10.1111/risa.12044.
Modeling population immunity to support efforts to end the transmission of live polioviruses
Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL
Risk Anal, 2013; 33(4):647-63. doi:10.1111/j.1539-6924.2012.01891.x.
Expert review on poliovirus immunity and transmission
Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM
Risk Anal, 2013; 33(4):544-605. doi:10.1111/j.1539-6924.2012.01864.x.
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs
Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM
Risk Anal, 2013; 33(4):606-46. doi:10.1111/risa.12031.
Global ICU: valuing prevention as the new paradigm in global health
Thompson KM
ICU Management 2012; 12(4):9-11.
Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response
Thompson KM, Wallace GS, Duintjer Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG
Public Health Rep, 2012; 127(1):23-37. doi:10.1177/003335491212700104.
Modeling poliovirus risks and the legacy of polio eradication
Thompson KM
Risk Anal, 2013; 33(4):505-15. doi:10.1111/risa.12030.
Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation
Thompson KM, Duintjer Tebbens RJ
Expert Rev Vaccines, 2012; 11(4):449-59. doi:10.1586/erv.11.195.
The role of risk analysis in polio eradication: modeling possibilities, probabilities and outcomes to inform choices
Thompson KM
Expert Rev Vaccines, 2012; 11(1):5-7. doi:10.1586/erv.11.163.
The probability of undetected wild poliovirus circulation after apparent global interruption of transmission
Kalkowska DA, Duintjer Tebbens RJ, Thompson KM
Am J Epidemiol, 2012; 175(9):936-49. doi:10.1093/aje/kwr399.
Economic analysis of the global polio eradication initiative
Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM
Vaccine, 2010; 29(2):334-43. doi:10.1016/j.vaccine.2010.10.026.
Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics
Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM
Epidemiol Infect, 2011; 139(6):836-48. doi:10.1017/S0950268810001676.
Optimal vaccine stockpile design for an eradicated disease: application to polio
Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM
Vaccine, 2010; 28(26):4312-27. doi:10.1016/j.vaccine.2010.04.001.
Priority shifting and the dynamics of managing eradicable infectious diseases
Duintjer Tebbens RJ, Thompson KM
Manag Sci, 2009; 55(4):650-63. doi:10.1287/mnsc.1080.0965.
Using system dynamics to develop policies that matter: global management of poliomyelitis and beyond
Duintjer Tebbens RJ, Thompson KM
Syst Dynam Rev, 2008; 24:433-49. doi:10.1002/sdr.
The risks, costs, and benefits of possible future global policies for managing polioviruses
Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander J, Jafari H, Cochi SL
Am J Public Health, 2008; 98(7):1322-30. doi:10.2105/AJPH.2007.122192.
The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation
Thompson KM, Duintjer Tebbens RJ
Medscape J Med, 2008; 10(8):190.
Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management
Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM
Risk Anal, 2008; 28(4):855-76. doi:10.1111/j.1539-6924.2008.01078.x.
Eradication versus control for poliomyelitis: an economic analysis
Thompson KM, Duintjer Tebbens RJ
Lancet, 2007; 369(9570):1363-1371. doi:10.1016/S0140-6736(07)60532-7.
Winner of 2008 Jay Forrester Award for best contribution to the field of System Dynamics during the preceding 5 years.
Eradicating polio: the dollars and sense
Thompson KM
MedGenMed, 2007; 9(4):11.
Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling
Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Caceres VM, Sangrujee N, Jafari H, Cochi SL
Risk Anal, 2006; 26(6):1571-80. doi:10.1111/j.1539-6924.2006.00841.x.
Evaluation of response scenarios to potential polio outbreaks using mathematical models
Thompson KM, Duintjer Tebbens RJ, Pallansch MA
Risk Anal, 2006; 26(6):1541-56. doi:10.1111/j.1539-6924.2006.00843.x.
The costs of future polio risk management policies
Tebbens RJ, Sangrujee N, Thompson KM
Risk Anal, 2006; 26(6):1507-31. doi:10.1111/j.1539-6924.2006.00842.x.
Global surveillance and the value of information: the case of the global polio laboratory network
de Gourville E, Duintjer Tebbens RJ, Sangrujee N, Pallansch MA, Thompson KM
Risk Anal, 2006; 26(6):1557-69. doi:10.1111/j.1539-6924.2006.00845.x.
Retrospective cost-effectiveness analyses for polio vaccination in the United States
Thompson KM, Duintjer Tebbens RJ
Risk Anal, 2006; 26(6):1423-40. doi:10.1111/j.1539-6924.2006.00831.x.
Poliomyelitis and the role of risk analysis in global infectious disease policy and management
Thompson KM
Risk Anal, 2006; 26(6):1419-21. doi:10.1111/j.1539-6924.2006.00853.x.
Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication
Duintjer Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM
Risk Anal, 2006; 26(6):1471-505. doi:10.1111/j.1539-6924.2006.00827.x.
Risk management in a polio-free world
Bruce Aylward R, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D
Risk Anal, 2006; 26(6):1441-8. doi:10.1111/j.1539-6924.2006.00840.x.
A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future
Duintjer Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Sutter RW, Thompson KM
Am J Epidemiol, 2005; 162(4):358-72. doi:10.1093/aje/kwi206.
Policy decision options during the first 5 years following certification of polio eradication
Sangrujee N, Duintjer Tebbens RJ, Caceres VM, Thompson KM
Medscape Gen Med, 2003; 5(4):35.
